This is a randomized, blinded, placebo-controlled Phase 1 b trial to evaluate the safety, tolerability, and immunological profile of INO-4500 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA™ 2000 device in healthy volunteers in Ghana.

On October 26, 2021, INOVIO announced this clinical trial has completed the enrollment of the 220 participants.